Authors: Natsuo Tomita Norihito Soga Yuji Ogura Norio Hayashi Takumi Kageyama Makoto Ito Yutaro Koide Maiko Yoshida Kana Kimura Chiyoko Makita Hiroyuki Tachibana Takeshi Kodaira
Publish Date: 2016/05/02
Volume: 142, Issue: 7, Pages: 1609-1619
Abstract
A total of 391 patients treated with HT between June 2006 and December 2013 were included in this retrospective study All patients received neoadjuvant ADT for a median duration of 10 months followed by HT at a median dose of 78 Gy interquartile range IQR 78–78 The times of median adjuvant and total ADT were 19 and 27 months IQR 20–31 respectively The risk stratification followed the 2015 National Comprehensive Cancer Network criteria Biochemical diseasefree survival bDFS followed the Phoenix definition Toxicity was scored according to the Radiation Therapy Oncology Group morbidity grading scaleMedian followup from HT start was 60 months IQR 42–81 Fiveyear bDFS rates for low intermediate high and veryhighrisk groups were 100 982 977 and 879 respectively We observed clinical relapse in nine veryhighrisk patients and one highrisk patient resulting in a 5year clinical relapsefree survival of 100 100 994 and 917 respectively for each risk group Three patients died of prostate cancer resulting in a 5year prostate cancerspecific survival of 996 The late grade 2 or higher gastrointestinal and genitourinary toxicities were 97 and 107 No cardiovascular fatal events were observed
Keywords: